Alpha memo: resveratrol inflammation induced signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Either (a) reframe the memo around a concrete, bounded empirical claim supported by the two receipts (e.g., 'resveratrol attenuates high-intensity exercise-induced intestinal inflammation in mice via Nrf2/FTH1/GPX4 but does not alter systemic IL-6 response to acute exercise in rats'), or (b) drop the cross-receipt 'boundary' framing entirely and treat this as two separate single-receipt evidence maps.
2. Correct the 'human' axis label for Receipt 2 — Receipt 2 is a mouse model, not human.
3. Verify Receipt 1's statistical claims against the original full text; the duplicated 'P > 0.05' appears to be a transcription error in the source excerpt and should not be reproduced uncritically.
4. Provide a substantive alpha: what specifically does Receipt 2 add (Nrf2/FTH1/GPX4 ferroptosis pathway in intestine) that Receipt 1 does not address (systemic IL-6/TNF-α in serum)? The contrast should be mechanistic and endpoint-specific, not a generic non-transfer claim.

Major issues

• The memo does not produce a clear, bounded research signal. The one-sentence alpha is a meta-statement ('does not carry one stable direction') rather than a substantive empirical finding, and the interpretation ('Receipt 1 signal does not automatically transfer to Receipt 2') is a methodological truism, not a research intelligence output.
• Receipt 1 and Receipt 2 are not directionally opposed in the way the memo implies. Receipt 1 reports acute exercise increased inflammatory markers (without testing resveratrol's protective effect as a primary finding), while Receipt 2 reports resveratrol attenuated high-intensity-exercise-induced inflammation. The memo's framing of a 'split' between the two receipts is contrived and not directly supported by reading the excerpts against each other.
• The 'Why this is surprising' claim is unsupported: there is nothing inherently surprising that two different exercise protocols (endurance vs high-intensity swimming) in different species (rats vs mice) and different tissues (systemic/serum vs intestinal) yield different inflammatory readouts. This is expected biology, not a novel boundary.
• The Bounded contrast incorrectly labels Receipt 2 axes as including 'human' — Receipt 2 is a mouse study. The source excerpt explicitly states 'mice were treated with swimming exercise protocol.' This is a factual error in the synthesis.
• Receipt 1 excerpt contains a typo/artifact ('P > 0.05' appears for both 'not affected' and 'significantly increased' findings), and the memo reproduces this without flagging it, which undermines source fidelity.

Minor issues

• The 'Next test' and 'Evidence gap' sections are generic calls for a 'matched design' without specifying which axis (species, dose, endpoint, modality) should be matched first.
• Title says 'resveratrol inflammation induced signal' but the memo's actual signal is about exercise-induced inflammation with resveratrol as a modulator — the framing is slightly imprecise.
• The memo's hedging is appropriate in form but obscures the fact that no clear directional claim is being made at all.

Reviewer note

This alpha memo attempts to frame two receipts on resveratrol and exercise-induced inflammation as a bounded comparison, but the resulting 'signal' is a methodological truism ('findings do not automatically transfer across settings') rather than an empirical research intelligence output. The two receipts are not in meaningful directional conflict: Receipt 1 reports acute exercise elevated inflammatory markers in rats (resveratrol's protective effect is not the primary finding), while Receipt 2 reports resveratrol attenuated high-intensity-exercise-induced intestinal inflammation and ferroptosis in mice via Nrf2/FTH1/GPX4. These are different endpoints, different tissues, different exercise modalities, and different species — comparing them as if they represent a single 'resveratrol / inflammation / induced' signal is misleading. The memo also contains a factual error (labeling Receipt 2 as involving 'human' axes when it is a mouse study) and reproduces a likely transcription error from Receipt 1's excerpt without verification. The falsifier, gap, and next-test sections are generic. The memo needs a scope reset: either commit to a concrete mechanistic claim grounded in Receipt 2's Nrf2/FTH1/GPX4 finding, or restructure around a specific axis of comparison (e.g., systemic vs intestinal inflammation, or endurance vs high-intensity exercise) with both receipts contributing evidence on that specific axis.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis